14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
RVMD vs AKRO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Revolution Medicines, Inc. (RVMD) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 1–6 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). RVMD carries a Unified Composite Score of 57.7/100 (HOLD) at $161.20 (N/M Forward P/E, -853.0% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. RVMD 57.7/100 HOLD), RVMD captures the overall institutional head-to-head verdict (1–6 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-853.0% vs. 0.0% operating margin) and revenue trajectory (-95.2% vs. +0.0% YoY).
Technical & Structure Timing Caution: RVMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.6); meanwhile AKRO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RVMD vs AKRO. Trailing 12-month operating profitability (RVMD -853.0% vs AKRO 0.0%) and valuation multiples (RVMD N/M vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ RVMD vs AKRO Key Questions & Quantitative Answers
As of Nov 20, 2026, Revolution Medicines, Inc. (RVMD) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 1–6 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). RVMD carries a Unified Composite Score of 57.7/100 (HOLD) at $161.20 (N/M Forward P/E, -853.0% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. RVMD 57.7/100 HOLD), RVMD captures the overall institutional head-to-head verdict (1–6 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-853.0% vs. 0.0% operating margin) and revenue trajectory (-95.2% vs. +0.0% YoY). Technical & Structure Timing Caution: RVMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.6); meanwhile AKRO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RVMD leads the Growth & Scale pillar: RVMD posts -95.2% YoY revenue growth and +0.0% YoY earnings growth on $198M TTM revenue (N/A gross margin, -853.0% operating margin), compared with AKRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, RVMD generates $198M in USD-normalized revenue versus N/A for AKRO. In operating R&D and SG&A reinvestment, RVMD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKRO.
RVMD and AKRO trade at balanced relative valuation multiples. RVMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RVMD (-93.6% ROE) versus AKRO (-34.5% ROE) capital efficiency.
In options market volatility and institutional positioning, RVMD carries 56.9% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.43x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.35β · 61% Vol realized risk). By comparison, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.